Does targeted-release formulation of Budesonide improve kidney function in primary IgA Nephropathy? Check out the VA by NSMC Intern Anant Pilawan on NefIgArd part B trial
Day 3 of Kidney Week. Sibeprenlimab and Balcinrenone on NEJM and Lancet, plus a couple of other non-kidneywk studies,
in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy
Does targeted-release formulation of Budesonide improve kidney function in primary IgA Nephropathy? Check out the VA by NSMC Intern Anant Pilawan on NefIgArd part B trial